Docon Technologies, a promoter entity of Thyrocare Technologies, sold 53.32 lakh equity shares for a total consideration of ₹667.69 crore at an average price of about ₹1,252.03 per share.
Following the stake sale, Docon Technologies continues to remain a promoter of the company. The promoter shareholding has, however, declined to 60.93% from 70.98% before the transaction.
At 1 pm, shares of Thyrocare Technologies were trading 1.5% higher at ₹1,270.80 on the NSE. The stock has gained nearly 40% so far in 2025.
/images/ppid_59c68470-image-176129002629344935.webp)

/images/ppid_a911dc6a-image-177077603394625504.webp)
/images/ppid_59c68470-image-177077512106794299.webp)
/images/ppid_59c68470-image-177077504615982639.webp)
/images/ppid_59c68470-image-177077515851590090.webp)
/images/ppid_59c68470-image-177077508321758455.webp)
/images/ppid_a911dc6a-image-177077322976413782.webp)
/images/ppid_59c68470-image-177077258165510745.webp)
/images/ppid_59c68470-image-177077272281824806.webp)
/images/ppid_59c68470-image-177077276056749159.webp)
/images/ppid_59c68470-image-177077261155977594.webp)